Categorynews

ReCode Therapeutics Announces Participation in Upcoming Investor Conferences

September 3, 2021 Off By BusinessWire

MENLO PARK, Calif. & DALLAS–(BUSINESS WIRE)–#PCD—ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences in September:

  • Wells Fargo Virtual Healthcare Conference

    Format:     Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings

    Date: Thursday, September 9, 2021

    Time: 12:00 – 12:30 p.m. ET

    23rd H.C. Wainwright & Co. Annual Global Investment Conference

    Format:     On-demand presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings

    Date: Monday, September 13, 2021

    Time: 7:00 a.m. ET

    UBS Biotechnology Private Company Symposium

    Format:     Presentation by David Lockhart, Ph.D., CEO and President; Julie Eastland, COO and CFO, will also participate in virtual 1×1 meetings

    Date: Wednesday, September 22, 2021

    Time: 12:00 – 12:30 p.m. ET

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

Contacts

Media Contact:
Will Zasadny

Canale Communications, Inc.

[email protected]
(619) 961-8848

Investor Contact:
Sarah McCabe

Stern Investor Relations

[email protected]
[email protected]